Compare Quest Diagnostics Inc (DGX) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $231.66 (market cap $25.48B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 4.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| DGX | SGOV | |
|---|---|---|
Market Cap | $25.48B | $114.40B |
Volume | 941,866 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $100.72 |
52-Week Low | $173.49 | $100.28 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
SGOV trades at $100.515 with minimal daily movement (+0.05%). The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent dividends of $0.30-0.31 per share were declared for H2-2026. The ETF focuses on short-term Treasury bonds, with institutional activity showing Envestnet reduced its position by 13.2% in Q2 2026.
The outlook remains cautious amid rising Treasury yields and bond market volatility. Higher interest rates could pressure short-term bond ETFs like SGOV, though they offer relative safety. Key risks include Fed policy shifts and inflation trends. Investors should weigh yield advantages against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
